Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

CompletedOBSERVATIONAL
Enrollment

218

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Hepatitis C
Interventions
DRUG

Peginterferon Lambda-1a (BMS-914143)

Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]

Trial Locations (75)

1090

Local Institution, Vienna

1119

Local Institution, Buenos Aires

1121

Local Institution, Buenos Aires

1181

Local Institution, Buenos Aires

1221

Local Institution, Buenos Aires

2000

Local Institution, Rosario

2010

Local Institution, Darlinghurst

2031

Local Institution, Randwick

2050

Local Institution, Camperdown

2139

Local Institution, Sydney

2145

Local Institution, Westmead

3000

Local Institution, Leuven

3004

Local Institution, Melbourne

3050

Local Institution, Parkville

3084

Local Institution, Heidelberg

4000

Local Institution, Liège

4029

Local Institution, Herston

4102

Local Institution, Woolloongabba

4120

Local Institution, Greenslopes

5000

Local Institution, Adelaide

7600

Local Institution, Mar del Plata

9410

Local Institution, Créteil

10676

Local Institution, Athens

20122

Local Institution, Milan

20142

Local Institution, Milan

20246

Local Institution, Hamburg

22003

Metropolitan Research, Annandale

27710

Duke University Medical Center, Durham

28100

Local Institution, Novara

30060

Gastrointestinal Specialists Of Georgia, Marietta

30303

Local Institution, Bucharest

32803

Orlando Immunology Center, Orlando

33604

Local Institution, Pessac

34295

Local Institution, Montpellier

44650

Local Institution, Guadalajara

45249

Consultants For Clinical Research, Cincinnati

46010

Local Institution, Valencia

48202

Henry Ford Health System, Detroit

50134

Local Institution, Florence

50524

Local Institution, Bucharest

54006

Local Institution, Thessaloniki

55905

Mayo Clinic, Rochester

56124

Local Institution, Cisanello (pisa)

69120

Local Institution, Heidelberg

75571

Local Institution, Paris

75679

Local Institution, Paris

76012

Texas Clinical Research Institute, Arlington

77030

St. Luke'S Episcopal Hospital - Baylor College Of Medicine, Houston

University Of Texas Health Science Center At Houston, Houston

Va Medical Center (151), Houston

78215

Texas Liver Institute, San Antonio

80131

Local Institution, Napoli

84123

Clinical Research Centers Of America, Murray

92024

Local Institution, Auckland

92037

Scripps Clinic, La Jolla

92118

Local Institution, Clichy

96813

The Queen'S Medical Center, Honolulu

98101

Virginia Mason Medical Center, Seattle

700506

Local Institution, Iași

06510

Yale University School Of Medicine, New Haven

3065 VIC

Local Institution, Fitzroy

L4L 4Y7

Toronto Digestive Disease Associates, Inc., Vaughan

00029

Local Institution, Hus

06202

Local Institution, Nice

00161

Local Institution, Viale Del Policlinico, 155

1105 AZ

Local Institution, Amsterdam

2333 ZA

Local Institution, Leiden

15-540

Local Institution, Bialystok

31-202

Local Institution, Krakow

50-220

Local Institution, Wroclaw

00927

Local Institution, San Juan

300 002

Local Institution, Timișoara

614-735

Local Institution, Busan

08003

Local Institution, Barcelona

08035

Local Institution, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01525810 - Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial | Biotech Hunter | Biotech Hunter